Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled …
FC Zhu, W Chen, YM Hu, Y Hong, J Li… - … Journal of Cancer, 2014 - Wiley Online Library
This phase II/III, double‐blind, randomized trial assessed the efficacy, immunogenicity and
safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in young …
safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in young …
Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized …
F Zhu, SY Hu, Y Hong, YM Hu, X Zhang… - Cancer …, 2017 - Wiley Online Library
We previously reported the results of a phase II/III, double‐blind, randomized controlled
study in Chinese women (NCT00779766) showing a 94.2%(95% confidence interval: 62.7 …
study in Chinese women (NCT00779766) showing a 94.2%(95% confidence interval: 62.7 …
Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised …
FC Zhu, SY Hu, Y Hong, YM Hu, X Zhang… - Cancer …, 2019 - Wiley Online Library
Background Cervical cancer is a major public health concern in China. We report the end‐of‐
study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the …
study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the …
Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized …
R Konno, S Tamura, K Dobbelaere… - International Journal of …, 2010 - ijgc.bmj.com
Background: Human papillomavirus (HPV) type 16/18 AS04-adjuvanted vaccine was shown
to be highly immunogenic and generally well tolerated in the interim analysis of a phase 2 …
to be highly immunogenic and generally well tolerated in the interim analysis of a phase 2 …
Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized …
R Konno, S Tamura, K Dobbelaere… - International Journal of …, 2010 - ijgc.bmj.com
Background: A phase 2 double-blind, controlled, randomized multicenter study with human
papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is ongoing in healthy Japanese …
papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is ongoing in healthy Japanese …
Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure …
A Szarewski, WAJ Poppe, SR Skinner… - … journal of cancer, 2012 - Wiley Online Library
Abstract In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)‐
16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly …
16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly …
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase …
SR Skinner, A Szarewski, B Romanowski, SM Garland… - The Lancet, 2014 - thelancet.com
Background Although adolescent girls are the main population for prophylactic human
papillomavirus (HPV) vaccines, adult women who remain at risk of cervical cancer can also …
papillomavirus (HPV) vaccines, adult women who remain at risk of cervical cancer can also …
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: results from 2 randomized controlled …
F Zhu, J Li, Y Hu, X Zhang, X Yang, H Zhao… - Human Vaccines & …, 2014 - Taylor & Francis
Immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted
vaccine were evaluated in healthy Chinese females aged 9–45 years in 2 phase IIIB …
vaccine were evaluated in healthy Chinese females aged 9–45 years in 2 phase IIIB …
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese …
R Konno, H Yoshikawa, M Okutani… - Human Vaccines & …, 2014 - Taylor & Francis
In this open, extended follow-up study (NCT00929526, Clinicaltrials. gov), we evaluated the
human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine efficacy, immunogenicity and …
human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine efficacy, immunogenicity and …
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post …
PS Naud, CM Roteli-Martins… - Human vaccines & …, 2014 - Taylor & Francis
HPV-023 (NCT00518336; ClinicalTrial. gov) is a long-term follow-up of an initial double-
blind, randomized (1: 1), placebo-controlled study (HPV-001, NCT00689741) evaluating the …
blind, randomized (1: 1), placebo-controlled study (HPV-001, NCT00689741) evaluating the …